- Price
- $102.55
- Day
- +0.31%
- Mkt Cap
- $177.45B
- 52W Range
- $81.97 – $137.49
- Volume
- 26.99M
- Beta
- 0.59
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Dividend Kings have a 50+ year track record of increasing dividends, showcasing resilience through economic challenges. I rank the Dividend Kings using my 9F Quality Scores, blending qualitative and quantitative factors for a robust, investment-grade assessment. ADP stands out as the best total-return candidate. It is undervalued, high-quality, and offering a strong projected dividend growth rate and Adjusted Chowder Number.
Read full article
Wall Street analysts have raised price targets on Abbott, citing accelerating growth in its Medical Devices segment. Abbott's diabetes, electrophysiology, and new Exact Sciences cancer-screening businesses are driving stronger sales and earnings.
Read full article
They have a knack for increasing their dividends even when facing challenges.
Read full article
ABBOTT PARK, Ill., Sept. 17, 2026 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 63 cents per share.
Read full article
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Read full article
It is certainly a good Dividend King to buy in September.
Read full article
Bank of America Corp DE purchased a new stake in Abbott Laboratories (NYSE: ABT) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 17,672,543 shares of the healthcare product maker's stock, valued at approximately $1,603,607,000. Bank of America Corp DE owned
Read full article
Abbott (ABT) closed the most recent trading day at $103.09, moving +1.12% from the previous trading session.
Read full article
Abbott Laboratories has agreed to pay more than $384 million to settle allegations related to contaminated infant formula, the U.S. Justice Department said on Monday.
Read full article
Settlement does not represent any finding of fault or liability As the government has previously indicated, it has closed its criminal investigation on this matter Tests by government regulators of unopened product from the homes of the infants under investigation at the time of the 2022 recall were negative for Cronobacter sakazakii No unopened, distributed Abbott infant formulas have ever tested positive for Cronobacter sakazakii ABBOTT PARK, Ill., Sept. 14, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) has reached an agreement to resolve the previously disclosed investigation and lawsuit brought by the United States Department of Justice, as well as lawsuits filed by certain relators and the Attorneys General of several states, relating to Abbott's manufacturing and 2022 recall of powdered infant formula at its facility in Sturgis, Mich.
Read full article
Citadel, Ken Griffin's hedge fund, materially increased its stake in AbbVie; here's why you may want to follow that lead.
Read full article
Both Medtronic and Abbott have raised their dividends for nearly half a century, but retirement investors with limited capital can only choose one.
Read full article